Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veliparib and Temozolomide in Relapsed or Refractory Small Cell Lung Cancer
NCT01638546Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2012
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of veliparib in small cell lung cancer (SCLC), sponsored by National Cancer Institute. Started Jul 2012; status: active, not recruiting.
02
Drugs
veliparib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01638546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01638546.